Subscribe
bill-oxford
Bill Oxford / IStockphoto.com
29 October 2018Americas

J&J reveals plans to appeal cancer drug court ruling

Johnson & Johnson (J&J) has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.
Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.
Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.

More on this story

Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.
Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB